Ainsley M Robinson1, Shakuntla V Gondalia, Avinash V Karpe, Rajaraman Eri, David J Beale, Paul D Morrison, Enzo A Palombo, Kulmira Nurgali. 1. *Centre for Chronic Diseases, College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia; †Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria, Australia; ‡Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, Victoria, Australia; §School of Health Sciences, University of Tasmania, Launceston, Tasmania, Australia; ‖CSIRO Land and Water, Brisbane, Queensland, Australia; and ¶Australian Centre for Research on Separation Science, RMIT University, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Dysbiosis of the gut microbiota may be involved in the pathogenesis of inflammatory bowel disease (IBD). However, the mechanisms underlying the role of the intestinal microbiome and metabolome in IBD onset and its alteration during active treatment and recovery remain unknown. Animal models of chronic intestinal inflammation with similar microbial and metabolomic profiles would enable investigation of these mechanisms and development of more effective treatments. Recently, the Winnie mouse model of colitis closely representing the clinical symptoms and characteristics of human IBD has been developed. In this study, we have analyzed fecal microbial and metabolomic profiles in Winnie mice and discussed their relevance to human IBD. METHODS: The 16S rRNA gene was sequenced from fecal DNA of Winnie and C57BL/6 mice to define operational taxonomic units at ≥97% similarity threshold. Metabolomic profiling of the same fecal samples was performed by gas chromatography-mass spectrometry. RESULTS: Composition of the dominant microbiota was disturbed, and prominent differences were evident at all levels of the intestinal microbiome in fecal samples from Winnie mice, similar to observations in patients with IBD. Metabolomic profiling revealed that chronic colitis in Winnie mice upregulated production of metabolites and altered several metabolic pathways, mostly affecting amino acid synthesis and breakdown of monosaccharides to short chain fatty acids. CONCLUSIONS: Significant dysbiosis in the Winnie mouse gut replicates many changes observed in patients with IBD. These results provide justification for the suitability of this model to investigate mechanisms underlying the role of intestinal microbiota and metabolome in the pathophysiology of IBD.
BACKGROUND:Dysbiosis of the gut microbiota may be involved in the pathogenesis of inflammatory bowel disease (IBD). However, the mechanisms underlying the role of the intestinal microbiome and metabolome in IBD onset and its alteration during active treatment and recovery remain unknown. Animal models of chronic intestinal inflammation with similar microbial and metabolomic profiles would enable investigation of these mechanisms and development of more effective treatments. Recently, the Winnie mouse model of colitis closely representing the clinical symptoms and characteristics of human IBD has been developed. In this study, we have analyzed fecal microbial and metabolomic profiles in Winnie mice and discussed their relevance to human IBD. METHODS: The 16S rRNA gene was sequenced from fecal DNA of Winnie and C57BL/6 mice to define operational taxonomic units at ≥97% similarity threshold. Metabolomic profiling of the same fecal samples was performed by gas chromatography-mass spectrometry. RESULTS: Composition of the dominant microbiota was disturbed, and prominent differences were evident at all levels of the intestinal microbiome in fecal samples from Winnie mice, similar to observations in patients with IBD. Metabolomic profiling revealed that chronic colitis in Winnie mice upregulated production of metabolites and altered several metabolic pathways, mostly affecting amino acid synthesis and breakdown of monosaccharides to short chain fatty acids. CONCLUSIONS: Significant dysbiosis in the Winnie mouse gut replicates many changes observed in patients with IBD. These results provide justification for the suitability of this model to investigate mechanisms underlying the role of intestinal microbiota and metabolome in the pathophysiology of IBD.
Authors: David J Beale; Farhana R Pinu; Konstantinos A Kouremenos; Mahesha M Poojary; Vinod K Narayana; Berin A Boughton; Komal Kanojia; Saravanan Dayalan; Oliver A H Jones; Daniel A Dias Journal: Metabolomics Date: 2018-11-17 Impact factor: 4.290
Authors: Lauren Sahakian; Rhiannon T Filippone; Rhian Stavely; Ainsley M Robinson; Xu Sean Yan; Raquel Abalo; Rajaraman Eri; Joel C Bornstein; Mark R Kelley; Kulmira Nurgali Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: David J Beale; Avinash V Karpe; Warish Ahmed; Stephen Cook; Paul D Morrison; Christopher Staley; Michael J Sadowsky; Enzo A Palombo Journal: Int J Environ Res Public Health Date: 2017-03-14 Impact factor: 3.390
Authors: Avinash V Karpe; Melanie L Hutton; Steven J Mileto; Meagan L James; Chris Evans; Rohan M Shah; Amol B Ghodke; Katie E Hillyer; Suzanne S Metcalfe; Jian-Wei Liu; Tom Walsh; Dena Lyras; Enzo A Palombo; David J Beale Journal: Metabolites Date: 2021-06-11
Authors: Mohammad I El Mouzan; Harland S Winter; Ahmed A Al Sarkhy; Kirill Korolev; Rajita Menon; Asaad A Assiri Journal: Saudi J Gastroenterol Date: 2021 May-Jun Impact factor: 2.485